Seven-Year PSA ≤ 0.2 ng/mL After High-Dose-Rate Brachytherapy Indicates Eligibility for Discontinuing PSA Surveillance in Prostate Cancer
Based on our long-term data, we propose that PSA monitoring may be safely discontinued in patients with a PSA level of ≤0.2 ng/mL 7 years after HDR-BT because the risk of recurrence beyond this point is exceedingly low.
Authors
- Hiroaki Iwamoto (ORCID: https://orcid.org/0000-0003-3599-2217)
- Takayuki Sakurai (ORCID: https://orcid.org/0000-0003-4573-0667)
- Takahiro Nohara (ORCID: https://orcid.org/0000-0001-9792-2068)
- Taiki Kamijima (ORCID: https://orcid.org/0009-0003-2553-0497)
- Renato Naito
- Atsushi Mizokami (ORCID: https://orcid.org/0000-0002-5643-2182)
- Shigeyuki Takamatsu (ORCID: https://orcid.org/0000-0002-0743-4413)
- Hiroshi Yaegashi (ORCID: https://orcid.org/0000-0003-3188-8834)
- Kazuyoshi Shigehara (ORCID: https://orcid.org/0000-0002-2118-9135)
- Ryunosuke Nakagawa (ORCID: https://orcid.org/0000-0002-2503-8908)
- Kouji Izumi (ORCID: https://orcid.org/0000-0002-8480-9100)
- Tomoyuki Makino (ORCID: https://orcid.org/0000-0003-2554-7048)
- Hiroshi Kano (ORCID: https://orcid.org/0000-0002-3543-1236)
Institutions
- Kanazawa University (JP)
Publication Details
- Journal
- Cancers
- Published
- 2025-09-28
- DOI
- https://doi.org/10.3390/cancers17193151
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00